This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Dibekacin
- DrugBank Accession Number
- DB13270
- Background
Dibekacin is an aminoglycoside antibiotic marketed in Japan 1.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Dibekacin (DB13270)
- Weight
- Average: 451.521
Monoisotopic: 451.264213171 - Chemical Formula
- C18H37N5O8
- Synonyms
- Dibekacin
- Dibekacina
- Dibekacine
- Dibekacinum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Bupivacaine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Dibekacin sulfate A0869I992Z 58580-55-5 GXKUKBCVZHBTJW-USXQJGOZSA-N
Categories
- ATC Codes
- S01AA29 — DibekacinJ01GB09 — Dibekacin
- Drug Categories
- Agents that produce neuromuscular block (indirect)
- Aminoglycoside Antibacterials
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Carbohydrates
- Drugs that are Mainly Renally Excreted
- Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
- Glycosides
- Narrow Therapeutic Index Drugs
- Nephrotoxic agents
- Ophthalmologicals
- Sensory Organs
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 4,6-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C6-positions.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- 4,6-disubstituted 2-deoxystreptamines
- Alternative Parents
- O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / 1,2-aminoalcohols / Oxacyclic compounds / Acetals / Primary alcohols show 3 more
- Substituents
- 1,2-aminoalcohol / 4,6-disubstituted 2-deoxystreptamine / Acetal / Alcohol / Aliphatic heteromonocyclic compound / Amine / Aminocyclitol or derivatives / Cyclic alcohol / Cyclitol or derivatives / Cyclohexanol show 15 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- kanamycins (CHEBI:37945)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 45ZFO9E525
- CAS number
- 34493-98-6
- InChI Key
- JJCQSGDBDPYCEO-XVZSLQNASA-N
- InChI
- InChI=1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
- IUPAC Name
- (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol
- SMILES
- NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1
References
- General References
- Institute of Microbial Chemistry - Japan - History [Link]
- External Links
- KEGG Drug
- D07811
- ChemSpider
- 413666
- 3328
- ChEBI
- 37945
- ChEMBL
- CHEMBL560976
- ZINC
- ZINC000008214383
- PDBe Ligand
- 84D
- Wikipedia
- Dibekacin
- PDB Entries
- 6cav / 8ifb / 8ifd
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection 50 mg/mL Solution / drops Ophthalmic - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 33.9 mg/mL ALOGPS logP -2.6 ALOGPS logP -5.3 Chemaxon logS -1.1 ALOGPS pKa (Strongest Acidic) 12.54 Chemaxon pKa (Strongest Basic) 9.84 Chemaxon Physiological Charge 5 Chemaxon Hydrogen Acceptor Count 13 Chemaxon Hydrogen Donor Count 9 Chemaxon Polar Surface Area 247.94 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 105.38 m3·mol-1 Chemaxon Polarizability 46.15 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0fb9-0900800000-fc0775c7da0f4f81d607 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0ufs-0900600000-1743314b775bfc16aff6 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0229-0894500000-316368ef461eae3615db Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0ugi-1935800000-933dccbed32cfa590279 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0gw1-6937200000-0f57c57d5ffb2bdcd49e Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-2395300000-dabd58ea939f036b5270 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 209.6950578 predictedDarkChem Lite v0.1.0 [M-H]- 197.77563 predictedDeepCCS 1.0 (2019) [M+H]+ 210.7334578 predictedDarkChem Lite v0.1.0 [M+H]+ 199.49934 predictedDeepCCS 1.0 (2019) [M+Na]+ 209.5838578 predictedDarkChem Lite v0.1.0 [M+Na]+ 205.82832 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:38 / Updated at February 21, 2021 18:54